Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements
- 17 June 2010
- journal article
- Published by Springer Science and Business Media LLC in Journal of Human Genetics
- Vol. 55 (9), 582-589
- https://doi.org/10.1038/jhg.2010.73
Abstract
The aim of the study is to improve our understanding of the worldwide allele frequency distribution of four genetic polymorphisms known to influence warfarin dosing (VKORC1 rs9923231, CYP2C9 rs1799853, CYP2C9 rs1057910 and CYP4F2 rs2108622). These four polymorphisms were genotyped in the Human Genome Diversity Project-Centre Etude Polymorphism Humain (HGDP-CEPH) worldwide sample (N=963), as well as in a sample of individuals of European, East Asian and South Asian ancestry living in Canada (N=316). The VKORC1 rs9923231 single nucleotide polymorphism (SNP) showed an extensive geographic differentiation, with the derived T allele appearing at very high allele frequencies in East Asian populations. Results from several tests of positive selection indicate that this unusual distribution may be the result of positive selection in East Asia. Understanding the worldwide distribution of markers determining warfarin dosing is important for the future application of pharmacogenomic-based algorithms to different population groups.Keywords
This publication has 42 references indexed in Scilit:
- Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsBlood, 2010
- CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic DosingPharmacogenomics, 2009
- Validation of Clinical Testing for Warfarin Sensitivity: Comparison of CYP2C9-VKORC1 Genotyping Assays and Warfarin-Dosing AlgorithmsThe Journal of Molecular Diagnostics, 2009
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin DosePLoS Genetics, 2009
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M VariantMolecular Pharmacology, 2009
- The largest prospective warfarin-treated cohort supports genetic forecastingBlood, 2009
- CYP4F2 genetic variant alters required warfarin dosePublished by American Society of Hematology ,2008
- Bleeding Complications With Warfarin UseArchives of Internal Medicine, 2007
- The physiology of vitamin K nutriture and vitamin K‐dependent protein function in atherosclerosisJournal of Thrombosis and Haemostasis, 2004
- Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic PolymorphismsThe Journal of Clinical Pharmacology, 2004